Tuesday, January 16, 2018 3:35:13 PM
At the end of every commercial for an approved drug, you will hear a long list of “talk to your doctor if you experience any of the following:” disclaimers. Here’s what a Lilly clinical VP told me about how those “side effects may include” warnings get included in the commercials:
“Other BP’s test the drugs (once approved and available) on samples of people with the 10 top ranked most common complaints in medicine - changes in mood, sleep patterns, blood pressure, nausea, vomiting, changes in bowel habits - diarrhea/constipation, blurry vision...
Then, they test the drug on a sample of people who are on the top 10 most widely prescribed medications to look for “interactions” - do not take if you are currently taking blood thinners, anti-depressants, blood pressure medications, cholesterol meds, sleeping pills, thyroid meds, ...
And then, they tie it up with a neat little bow disclaiming every common condition: Do not take if you have diabetes, have experienced a cardiac event in the past (including murmurs, flutters, arrhythmias) have diabetes, history of seizures, are pregnant or may become pregnant...and so forth.”
So, it appears that every drug HAS all of these side effects. The fact is that none of these are found during the trial/testing phase because new drugs are treated in very select people with no complicating factors in order to try to get a 1 to 1 correlation of efficacy of the drug to the indication without noise distortion. The FDA does not make companies test against all other possible interactions before approval in case you haven’t noticed. They want to get a sense of the purest possible cause-effect relationship between a drug and efficacy and side effects caused only by that specific compound.
Attention...
It is the other BP’s doing strategic business which make the case for so many possible “outside” factors entering into the picture, that we are all left with the impression that every drug is just too dangerous or unpleasant to warrant taking it. It’s smart business - give the appearance that these are side effects of the actual drug alone. And all BP’s do it. It called “giving a clean drug side effects” if it works. (And don’t forget: do not use when operating machinery or mix with alcohol...I think that pretty much covers everything - DO NOT TAKE THIS DRUG EVER/ANYBODY!)
Here’s the chess move:
If Dr. Missling/Anavex and the SAB are able to show IMPROVEMENT in the most common areas of unwanted effects experienced by the vast majority of people, does that not “disarm” the coming attack from BP? So far, A2-73 COULD/MAY/MIGHT help treat certain indications affecting certain segments of the population (older - ALZ, younger - Rett, mid-age - PD), which won’t be known until after trials are performed and completed. But, if you are confident in the probable outcome of your trial (KEM analysis), and you gain approval, what kind of protection can you put into place against other BP’s hurting your market with their bag of pre-loaded contraindications? One way might be to offer clinical research that area’s most affected are actually improved by your drug. So let’s see, we have insomnia off the list, and mood changes in the “elevated” and therefore positive column. Add to that: improvement in cardiovascular areas of risk such as elevated blood pressure, and take seizures off the list...
You see where I’m going - the case I’m building.
So, if we can remove blurry vision - Shout out to MAC!!! - and get risk of stroke (which also involves high blood pressure), off the list, we simply need to address gastric effects (the gut biome gambit might turn something up there), and what is left is safe for every one (btw, someone mentioned high blood pressure affects our brave Rett heroines, and, I’m sure there is cross over in the AD/PD population of many of the common symptoms). No contraindications.
Then, add RWE, and the public feedback portion of the new transparent clinical trial reviews (a window into how the sausage is made) and you have a recipe for one helluva successful drug launch - ONCE EFFICACY ABOVE SOC IS ESTABLISHED.
That’s when people would clamor for it - especially in these devastating CNS diseases with no effective treatments. Just show the patients and caregivers that they (both) will sleep better, be happier, not be at increased risk for MI or stroke - possibly lower that risk, possibly improve vision, but not blur it, possible normal gastric ramifications...this is all symptom related, but it’s all good, even great!
Check mate; cocktails for everyone!
I think Missling is not letting us down - our own shortsightedness is. I do not agree that the only strategy is “start the trials and see what we got”. That’s checkers thinking; just think one jump ahead. Recipe for a thoughtless loss. If we get to the wall and get “kinged” or “crowned”, what the heck good is it if someone is waiting to immediately take back your achievement by jumping your king on the very next move? These strategies are all set up and ready to go as attested to by BP employees, and they’re legal, and make good business sense.
Does anyone want to win this “game”? I think Missling does. Does anyone want to think longer term and patiently to guarantee we still have options to succeed and win 10 moves down the road? I think Missling does.
Don’t move until you see it, right?
Looks like a lot of smaller pieces are coming together for a marvelous end game to me. Never mind the middle ground - that’s where most people/players/drug developers/BP CEO’s have made their fatal errors in the past.
Just mvho,
Bio
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM